Egetis is trying to turn a rare-disease drug into a real business, with early progress in Europe and a clearer path toward a U.S. decision that could unlock a much bigger market. The key question is whether patient access and pricing come through fast enough to outrun delays, pushback from payers, and ongoing funding needs.Read more
Catalysts About Egetis Therapeutics Egetis Therapeutics develops and commercializes treatments for rare endocrine and genetic disorders, with a focus on MCT8 deficiency. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Egetis Therapeutics Egetis Therapeutics is a specialty biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare endocrine and metabolic disorders. What are the underlying business or industry changes driving this perspective?Read more
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
